Cosimo Lobello Selected Research

ruxolitinib

1/2020

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cosimo Lobello Research Topics

Disease

4	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021 - 03/2018
3	Neoplasms (Cancer) 12/2023 - 01/2020
2	T-Cell Lymphoma (Lymphoma, T Cell) 12/2023 - 01/2021
1	Lymphoma (Lymphomas) 10/2020
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Genomic Instability 03/2018

Drug/Important Bio-Agent (IBA)

3	Anaplastic Lymphoma KinaseIBA 01/2021 - 03/2018
2	NucleophosminIBA 10/2020 - 03/2018
1	NAD (NADH)IBA 12/2023
1	EnzymesIBA 12/2023
1	Phosphotransferases (Kinase)IBA 12/2023
1	CrizotinibIBA 10/2020
1	Interleukin-10 ReceptorsIBA 10/2020
1	Proteins (Proteins, Gene)FDA Link 10/2020
1	RNA (Ribonucleic Acid)IBA 10/2020
1	ruxolitinibIBA 01/2020
1	Janus Kinase InhibitorsIBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2018

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2021
1	Breast Implants (Breast Implant) 01/2021
1	Therapeutics 10/2020